You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm has a molecular SARS-CoV-2 test in development on its Revogene platform and will be distributing an antigen test.
The test is designed to save resources by testing for the four viruses in one test using single nasopharyngeal, oropharyngeal, or nasal swab samples.
The reissued Emergency Use Authorization from the US Food and Drug Administration also permits the test's use in asymptomatic individuals, the firm said.
The European Commission recently awarded the company a two-year, €2.6 million Horizon 2020 grant to achieve its ambitions.
The test confirms the presence of antibodies directed to various gene products of HIV-1 and HIV-2 in human serum or plasma.
Wren Laboratories and P23 Labs received revised EUAs that allow their previously authorized tests to now be used with new specimen types.
Driven by potential advantages like high throughput, a number of groups have pursued mass spec-based tests, but assay performance has hindered these efforts.
The firm said that its core business, excluding COVID-19 clinical testing revenues, returned to positive organic growth in the quarter.
The firm saw 120 percent growth in the BioFire FilmArray product line driven by strong demand for a respiratory panel which can detect SARS-CoV-2.
The revenue increase was driven by significant growth in the conglomerate's life sciences segment.
The third quarter continued Abbott's streak of offsetting base business declines with COVID-19 testing, with 38 percent growth in the diagnostics business.
The firm reported $2 billion in third-quarter revenues related to the COVID-19 response, accounting for 23 percent of its overall revenues.
The firms previously received CE mark for a COVID-19 test on the BD Max system in March.
The firm's variety of COVID-19 molecular and immunoassay test offerings offset declines in the point-of-care segment.
The German diagnostics firm expects more than €80 million in 2020 revenues, driven by its recovering core business and its COVID-19 testing business.
The collaboration will involve the evaluation of serological tests to detect the durability of patients' immune response to COVID-19.
The company said it could produce 3 million antigen tests before the end of this year and between 15 million and 20 million tests per month starting next year.
The US Department of Health and Human Services (HHS) said that it would use Fluidigm's saliva-based molecular SARS-CoV-2 test as part of a federal surge testing program.
Thermo Fisher's test is now authorized for use with the Everlywell COVID-19 Test Home Collection Kit, which enables individuals to self-collect nasal swab specimens.
The assay does not require nucleic acid extraction or purification, unlike a LumiraDx SARS-CoV-2 test that received Emergency Use Authorization in August.